AstraZeneca on Thursday said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, raising ...

AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...

UBS analyst Matthew Weston maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of £115.00. The company’s shares opened today at p11,364.00.

The company said, “In relation to the illegal drug importation allegations, in January 2025, AstraZeneca (AZN) received a Notice of Transfer to the Prosecutor and an Appraisal Opinion from the ...

AstraZeneca has warned it could face a fine in China over possible unpaid import taxes, as it revealed strong sales of cancer drugs helped lift revenues higher. The FTSE 100-listed drugmaker said ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

AstraZeneca Pharma India Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 19,029.63 Crore) operating in Pharmaceuticals sector. AstraZeneca Pharma India Ltd. key ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...